Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics Earns US Patent for 47 BRCA1 Gene Mutations


SALT LAKE CITY--Myriad Genetics here has received a patent for 47 different BRCA1 gene mutations that increase the risk of breast and ovarian cancer. The company also received a notice of allowance from the US Patent and Trademark Office for four additional BRCA1 patent applications, including use of the gene or its protein as a breast cancer diagnostic.

Myriad said it will now use its proprietary functional genomic tools, including its ProNet database, to try to uncover the gene's biological role in the disease process.

In related news, the same day it won the patent--December 2--Myriad filed a lawsuit against OncorMed for patent infringement on the BRCA1 gene in the US District Court of Utah. OncorMed, based in Gaithersburg, Md., also has a patent on the BRCA1 gene and said it intends to fight the lawsuit. "Every major gene can be expected to be associated with multiple patents and BRCA1 is no exception," the company stated.

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.